The alarming rate of obesity and weight gain in industrialized nations is one of the most concerning health issues plaguing developed countries today. Scientists might have just come much closer to finally ending this epidemic by preventing mice from gaining weight even with a steady diet of high-fat food. Could these findings lead to effortless weight loss?
Published on eLife, the study described how scientists from Washington University School of Medicine basically activated certain pathways in fat cells, which essentially allowed the mice to go on a high-fat diet without becoming obese. This could lead to some huge leaps in treating all the other diseases that are associated with weight gain, including type-2 diabetes.
“Here by inducing expression of constitutively active Smoothened (SmoM2) or Gli2 (ΔNGli2) in the adipocyte lineage of postnatal mice, we show that targeted activation of Hh signaling suppresses high-fat-diet-induced obesity and improves whole-body glucose tolerance and insulin sensitivity,” the study reads.
As senior investigator Fanxin Long, Ph.D. put it, these findings could lead to new ways to treat the growing obesity epidemic afflicting populations even in developing countries. It also makes preventing weight gain easier because it targets the root cause of the issue.
"This could lead us to a new therapeutic target for treating obesity," Long said. "What's particularly important is that the animals in our study ate a high-fat diet but didn't gain weight, and in people, too much fat in the diet is a common cause of obesity."
On that note, translating the results of this study to apply to humans might not be that easy, MedicalXpress reports. The test subjects and people don’t exactly have the same metabolism and the methods used to activate the pathways in fat cells to stop them from growing might cause unknown side-effects. It might even cause cancer if the application is not done properly.


Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 



